Li Meina, Zhang Qi, Zhao Wen, Chen Juan, Liu Yinghua, Zhou Limian, Liu Yihui, Wang Langrun, Guan Yiran, He Jian, Jiang Qiuyue, Zeng Zhaozhong, Guo Xinmei, Liu Can, Zhang Liwei, Zhang Yong, Luo Jie, Hung Wei-Lian, He Jingjing, Wang Ran
Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China; College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin, China.
Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
J Nutr Health Aging. 2025 Aug;29(8):100598. doi: 10.1016/j.jnha.2025.100598. Epub 2025 Jun 10.
Research on effects of synbiotics in older adults with functional constipation (FC) is limited. This randomized, double-blind, placebo-controlled trial evaluated a 4-week synbiotic (Bifidobacterium animalis subsp. lactis BL-99 and fructooligosaccharides [FOS]) intervention in 67 participants ≥60 years old meeting Rome IV FC criteria. Compared to placebo, the synbiotic group showed significant improvements in weekly spontaneous bowel movements (Least squares mean ± standard error: 4.94 ± 0.25 vs. 3.00 ± 0.26, P < 0.001) and whole gut transit time (37.13 ± 3.78 vs. 50.64 ± 4.22 h, P = 0.019), with benefits sustained 2 weeks post-intervention. It also reduced time per toilet attempt and alleviated rectal discomfort symptoms more effectively than placebo. Fecal microbiome analysis revealed increased abundance of beneficial Bifidobacterium species, correlating with symptom improvement (P < 0.05). These findings demonstrate that BL-99/FOS supplementation ameliorates FC symptoms in older adults, with effects sustained post-discontinuation, potentially mediated through gut microbiota modulation. Further mechanistic investigation is warranted.
关于合生元对老年功能性便秘（FC）患者影响的研究有限。这项随机、双盲、安慰剂对照试验评估了为期4周的合生元（动物双歧杆菌乳酸亚种BL-99和低聚果糖[FOS]）干预对67名年龄≥60岁且符合罗马IV型FC标准的参与者的影响。与安慰剂相比，合生元组每周的自发排便次数有显著改善（最小二乘均值±标准误：4.94±0.25对3.00±0.26，P<0.001），全肠道转运时间也显著改善（37.13±3.78对50.64±4.22小时，P=0.019），干预后2周仍保持有益效果。与安慰剂相比，它还减少了每次排便尝试的时间，并更有效地缓解了直肠不适症状。粪便微生物群分析显示有益双歧杆菌种类的丰度增加，与症状改善相关（P<0.05）。这些发现表明，补充BL-99/FOS可改善老年人的FC症状，停药后效果仍持续，可能是通过调节肠道微生物群介导的。有必要进行进一步的机制研究。
